Page 5 - நடுவில் அமெரிக்கா இதயம் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is designed to evaluate the use of Veltassa® in enabling patients to remain on RAASi therapy in HF patients with or at high risk for HK Topline results are anticipated in 2024 Regulatory News: Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high risk for HK). This non-interventional clinical study aims to better understand renin-angiotensin-aldosterone system inhibitors (RAASi) treatment decisions in clinical practice, potential barriers to achieving optimal guideline-directed care in HF patients with or at high risk for HK, and to assess how Veltassa® may be u

Coll cardiolVifor pharmaMikhail kosiborodStefan ankerKlaus henning jensenResearch at saint luke health systemSwiss stock exchangeSaint luke mid america heart instituteVifor pharma groupProfessor of medicine at university missouriSwiss exchangeFresenius medical careSaint lukeMid america heart instituteVice presidentHealth system